Document Detail


Report on various clinical studies on high dose methotrexate in Europe (non EORTC).
MedLine Citation:
PMID:  7041027     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
High dose Methotrexate (HDMtx) is used in the therapy of a broad variety of human tumors. This review reports on completed, ongoing, or planned clinical trials or experience with HDMtx in individual therapy modalities. It is stressed that HDMtx-therapy should solely be given by highly skilled and experienced clinical oncologists, who are able to prevent toxicity and unnecessary side effects by determining Mtx-serum-levels, urine pH, fluid balance and detect clinical indicators for toxicity early enough to escape fatal organ damages.
Authors:
V Diehl
Related Documents :
3479917 - A clinical trial in oral surgery of the analgesic efficacy of a suprofen/codeine combin...
18515887 - Cognitive-behavioural therapy for severe mental disorders: back to the future?
18690437 - Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the...
18380637 - Practical guidelines for economic evaluations alongside equivalence trials.
20180697 - Apipuncture treatment for central post-stroke pain.
16801847 - Myocarditis presenting as gastritis in children.
Publication Detail:
Type:  Clinical Trial; Journal Article; Review    
Journal Detail:
Title:  Onkologie     Volume:  4     ISSN:  0378-584X     ISO Abbreviation:  Onkologie     Publication Date:  1981 Dec 
Date Detail:
Created Date:  1982-06-14     Completed Date:  1982-06-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7808556     Medline TA:  Onkologie     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  308-19     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Europe
Female
Humans
Male
Methotrexate / administration & dosage*,  adverse effects,  therapeutic use
Neoplasms / drug therapy*
Osteosarcoma / drug therapy
Chemical
Reg. No./Substance:
59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combined chemo- and radiotherapy in small cell bronchogenic carcinoma
Next Document:  Possibilities and limitations of radiotherapy in neoplasms of the anterior cranial fossa